Research Articles - Macular Degeneration
- To help people with retinal degenerative diseases better understand issues related to cataracts and their removal, Foundation-funded clinicians Richard Weleber, M.D., of the Casey Eye Institute, Oregon Health & Science University, and Jacque Duncan, M.D., of the University of California, San Francisco, provide the following answers to commonly asked questions:
Promising reports from several human studies for emerging retinal disease treatments highlighted the 2012 meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Ft. Lauderdale, Florida, May 6-10. As the world’s largest eye-research event, the meeting convened more than 12,000 doctors, scientists and industry professionals, who attended thousands of presentations on the latest
An emerging therapy to slow the progression of geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), has performed encouragingly in an 18-month, Phase II clinical trial involving 143 participants. The results provide some optimism for preserving vision from a leading cause of blindness in people over 50 in developed countries.
Though age-related macular degeneration (AMD) is a highly prevalent and blinding retinal disease affecting more than 10 million Americans, its cause has been a tough nut for researchers to crack, because of the multiple genetic and lifestyle factors that come into play. For decades, getting to the root causes of AMD has been challenging.
But in a research paper published in the October 6, 2011 journal Nature, an international group of scientists, including the Foundation-funded investigator
- Researchers have determined that identifying the genes linked to a person’s wet age-related macular degeneration (AMD) does not predict how well the drugs Lucentis® or Avastin® will save or restore their vision. Their findings are based on an analysis of people participating in the Comparison of AMD Treatment Trials (CATT). Results of the analysis were published in January in the journal Ophthalmology.
Acucela Inc., a Seattle-based developer of eye-disease therapies, is enrolling 440 patients across 56 sites for its three-year, Phase 2b/3 clinical trial of emixustat hydrochloride (formerly ACU-4429) for the treatment of advanced dry age-related macular degeneration (AMD), a vision-robbing retinal condition also known as geographic atrophy (GA). In August, the company reported that it reached 50 percent enrollment for the study.
A new study published in the journal Ophthalmology indicates that the beneficial effects of Lucentis, a popular treatment for wet age-related macular degeneration (AMD) developed by Genentech, may diminish over time for some patients. While Lucentis stabilized or improved vision in 90 percent of people with wet AMD participating in two-year clinical trials, study results
A research team from Germany and the Netherlands found that people from their countries who reported having allergies had a significantly reduced risk for age-related macular degeneration (AMD). Results of the study, which involved 3,585 Caucasian individuals, were reported in the journal Investigative Ophthalmology & Visual Science. The study was led